AUG 13, 2026 · PHASE 3 TRIAL
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
ClinicalTrials.gov
This is a Phase 3 trial registration with no posted results; the study is active but not recruiting, and efficacy and safety outcomes have not yet been reported.
Reported
Phase3
Planned enrollment630
Primary endpointOverall Survival, 36 months